Factor V Leiden and hepatic artery thrombosis after liver transplantation

Ty B. Dunn, Michael A. Linden, Gregory M. Vercellotti, Rainer W G Gruessner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Factor V Leiden (FVL) and other thrombophilias can be acquired during liver transplantation and can have a significant impact on clinical outcomes as well as cost. Standard practice does not include screening deceased donors for heritable thrombophilias, even if they have a personal history of thrombosis. Here we report a case of hepatic artery thrombosis in a liver recipient whose native and donor livers were heterozygous for FVL. The patient subsequently underwent a successful retransplant. FVL and its variants are expressed phenotypically as activated protein C (APC) resistance. We believe that testing liver donors (deceased or living) for APC resistance - a surrogate marker for the most common liver-based thrombophilia - will reduce the incidence of thrombotic events by identifying a need for posttransplant prophylactic anticoagulation in patients at risk. The estimated cost of testing all liver donors in the US for APC resistance is less than the cost of two complications secondary to thrombosis. Testing for APC resistance may further improve outcome and reduce cost after liver transplantation.

Original languageEnglish (US)
Pages (from-to)132-135
Number of pages4
JournalClinical Transplantation
Volume20
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Hepatic Artery
Activated Protein C Resistance
Liver Transplantation
Thrombosis
Liver
Costs and Cost Analysis
Tissue Donors
Donor Selection
Thrombophilia
Biomarkers
factor V Leiden
Incidence

Keywords

  • Cost
  • Hepatic artery
  • Prophylaxis
  • Surgical complications
  • Thrombophilia

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Factor V Leiden and hepatic artery thrombosis after liver transplantation. / Dunn, Ty B.; Linden, Michael A.; Vercellotti, Gregory M.; Gruessner, Rainer W G.

In: Clinical Transplantation, Vol. 20, No. 1, 01.2006, p. 132-135.

Research output: Contribution to journalArticle

Dunn, Ty B. ; Linden, Michael A. ; Vercellotti, Gregory M. ; Gruessner, Rainer W G. / Factor V Leiden and hepatic artery thrombosis after liver transplantation. In: Clinical Transplantation. 2006 ; Vol. 20, No. 1. pp. 132-135.
@article{aea707362567474487488e2881fbbfbb,
title = "Factor V Leiden and hepatic artery thrombosis after liver transplantation",
abstract = "Factor V Leiden (FVL) and other thrombophilias can be acquired during liver transplantation and can have a significant impact on clinical outcomes as well as cost. Standard practice does not include screening deceased donors for heritable thrombophilias, even if they have a personal history of thrombosis. Here we report a case of hepatic artery thrombosis in a liver recipient whose native and donor livers were heterozygous for FVL. The patient subsequently underwent a successful retransplant. FVL and its variants are expressed phenotypically as activated protein C (APC) resistance. We believe that testing liver donors (deceased or living) for APC resistance - a surrogate marker for the most common liver-based thrombophilia - will reduce the incidence of thrombotic events by identifying a need for posttransplant prophylactic anticoagulation in patients at risk. The estimated cost of testing all liver donors in the US for APC resistance is less than the cost of two complications secondary to thrombosis. Testing for APC resistance may further improve outcome and reduce cost after liver transplantation.",
keywords = "Cost, Hepatic artery, Prophylaxis, Surgical complications, Thrombophilia",
author = "Dunn, {Ty B.} and Linden, {Michael A.} and Vercellotti, {Gregory M.} and Gruessner, {Rainer W G}",
year = "2006",
month = "1",
doi = "10.1111/j.1399-0012.2005.00432.x",
language = "English (US)",
volume = "20",
pages = "132--135",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Factor V Leiden and hepatic artery thrombosis after liver transplantation

AU - Dunn, Ty B.

AU - Linden, Michael A.

AU - Vercellotti, Gregory M.

AU - Gruessner, Rainer W G

PY - 2006/1

Y1 - 2006/1

N2 - Factor V Leiden (FVL) and other thrombophilias can be acquired during liver transplantation and can have a significant impact on clinical outcomes as well as cost. Standard practice does not include screening deceased donors for heritable thrombophilias, even if they have a personal history of thrombosis. Here we report a case of hepatic artery thrombosis in a liver recipient whose native and donor livers were heterozygous for FVL. The patient subsequently underwent a successful retransplant. FVL and its variants are expressed phenotypically as activated protein C (APC) resistance. We believe that testing liver donors (deceased or living) for APC resistance - a surrogate marker for the most common liver-based thrombophilia - will reduce the incidence of thrombotic events by identifying a need for posttransplant prophylactic anticoagulation in patients at risk. The estimated cost of testing all liver donors in the US for APC resistance is less than the cost of two complications secondary to thrombosis. Testing for APC resistance may further improve outcome and reduce cost after liver transplantation.

AB - Factor V Leiden (FVL) and other thrombophilias can be acquired during liver transplantation and can have a significant impact on clinical outcomes as well as cost. Standard practice does not include screening deceased donors for heritable thrombophilias, even if they have a personal history of thrombosis. Here we report a case of hepatic artery thrombosis in a liver recipient whose native and donor livers were heterozygous for FVL. The patient subsequently underwent a successful retransplant. FVL and its variants are expressed phenotypically as activated protein C (APC) resistance. We believe that testing liver donors (deceased or living) for APC resistance - a surrogate marker for the most common liver-based thrombophilia - will reduce the incidence of thrombotic events by identifying a need for posttransplant prophylactic anticoagulation in patients at risk. The estimated cost of testing all liver donors in the US for APC resistance is less than the cost of two complications secondary to thrombosis. Testing for APC resistance may further improve outcome and reduce cost after liver transplantation.

KW - Cost

KW - Hepatic artery

KW - Prophylaxis

KW - Surgical complications

KW - Thrombophilia

UR - http://www.scopus.com/inward/record.url?scp=33644812921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644812921&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00432.x

DO - 10.1111/j.1399-0012.2005.00432.x

M3 - Article

VL - 20

SP - 132

EP - 135

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -